Please login to the form below

Not currently logged in
Email:
Password:

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

  • Bayer pins hopes on five potential blockbusters Bayer pins hopes on five potential blockbusters

    Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched

  • FDA fast-tracks Bayer's prostate cancer radiotherapy FDA fast-tracks Bayer's prostate cancer radiotherapy

    Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review

  • Bayer points to four blockbusters in portfolio

    Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.

  • Bayer's prostate cancer drug fast-tracked

    Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics